Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Efficacy of Bladder EpiCheck® for the Primary Detection of Urothelial Carcinoma in Subjects Presenting With Haematuria

NCT06818136 is registered in ClinicalTrials.gov with Nucleix Ltd. as lead sponsor.

NCT NCT06818136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06818136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Efficacy of Bladder EpiCheck® for the Primary Detection of Urothelial Carcinoma in Subjects Presenting With Haematuria
Lead sponsor
Nucleix Ltd.
Phase
Observational
Overall status
Recruiting
Start date
June 20, 2025
Completion date
December 31, 2026
Enrollment
800 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cystoscopy, hematuria, urothelial carcinoma bladder, urothelial carcinoma of the renal pelvis and ureter, urothelial carcinoma of the urinary bladder